← Leaderboards
Ananda Basu
Mayo Clinic
$10,492,691
Attributed
$17,186,485
Total exposure
8
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.2M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,467,810 · 9
By mechanism
R01$8,701,557 · 2
DP3$8,167,405 · 2
P30$1,281,325 · 1
T32$286,212 · 1
M01$31,311 · 3
Top collaborators
- Yogish C. Kudva5 shared
- Mary E Patti3 shared
- Francis J Doyle2 shared
- Boris P. Kovatchev2 shared
- Sue A Brown1 shared
- Claudio Cobelli1 shared
- Linda A Gonder-Frederick1 shared
- Jordan Pinsker1 shared
Others in their field
Top investigators on “Insulin”
- Jeffrey P Krischer · University Of South Florida$605,714,892
- John M Lachin · George Washington University$153,440,346
- David M Nathan · Massachusetts Institute Of Technology$139,041,931
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$108,827,660
- Mark A Magnuson · Vanderbilt University$79,749,111
- Jose A Luchsinger · Columbia University Health Sciences$71,267,462
Research focus
InsulinPhysiologyHypoglycemiaBaseAlgorithmsHyperglycemiaGlucoseClinical ResearchComputer SimulationInsulin-Dependent Diabetes MellitusKineticsDesignResponseGlucagonMonitorTracerHepaticInnovationPhysiologicalAppearancePreventSubcutaneousInfusion ProceduresExercise
Grant awards (24)
UAB Diabetes Research Center$1,281,325
P30 · FY2025 · DK · contact PI
Glucagon Pump Therapy for Post-Bariatric Hypoglycemia: Merging Physiology and Engineering$715,307
R01 · FY2025 · DK
Glucagon Pump Therapy for Post-Bariatric Hypoglycemia: Merging Physiology and Engineering$690,723
R01 · FY2024 · DK
Glucagon Pump Therapy for Post-Bariatric Hypoglycemia: Merging Physiology and Engineering$745,625
R01 · FY2023 · DK
Research Training in Neuroendocrinology and Metabolism$286,212
T32 · FY2022 · DK · contact PI
Integrated Approaches to Close the Loop in Type 1 Diabetes$318,369
R01 · FY2021 · DK · contact PI
Integrated approaches to close the loop in type 1 diabetes$222,487
R01 · FY2021 · DK · contact PI
Integrated approaches to close the loop in type 1 diabetes$604,353
R01 · FY2020 · DK · contact PI
Integrated approaches to close the loop in type 1 diabetes$611,508
R01 · FY2019 · DK · contact PI
Integrated approaches to close the loop in type 1 diabetes$634,997
R01 · FY2018 · DK · contact PI
Integrated approaches to close the loop in type 1 diabetes$655,099
R01 · FY2017 · DK · contact PI
Relative Efficacy of Single-, Bi-, and Tri-Hormonal Closed-Loop Control Systems$2,495,873
DP3 · FY2015 · DK · contact PI
Relative Efficacy of Single-, Bi-, and Tri-Hormonal Closed-Loop Control Systems$1,027,779
DP3 · FY2015 · DK · contact PI
Ambulatory Artificial Pancreas: merging physiology, behavior, and control design$101,175
DP3 · FY2014 · DK
Integrated approaches to close the loop in type 1 diabetes$717,961
R01 · FY2013 · DK
Integrated approaches to close the loop in type 1 diabetes$747,802
R01 · FY2012 · DK
Ambulatory artificial pancreas: merging physiology, behavior, and controldesign$4,542,578
DP3 · FY2011 · DK
Integrated approaches to close the loop in type 1 diabetes$631,882
R01 · FY2011 · DK
Integrated approaches to close the loop in type 1 diabetes$689,948
R01 · FY2010 · DK
Integrated approaches to close the loop in type 1 diabetes$715,496
R01 · FY2009 · DK
MEASUREMENT OF NITRIC OXIDE IN HUMANS: A PILOT STUDY$948
M01 · FY2005 · RR
PIOGLITAZONE ON BODY COMPOSITION, ENERGY BALANCE, VASCULAR FUNCTION AND MEAL TOL$237
M01 · FY2005 · RR
Pioglitazone--Body Density/bioenergenetic/CV Function$26,650
M01 · FY2004 · RR
Rituximab (Rituxan) in Autoimmune Hypoglycemia Syndrome$3,476
M01 · FY2004 · RR